2022 World Conference on Lung Cancer (ePosters)-EP08.01-053. PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs

EP08.01-053. PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs

Back to course

Pdf Summary

A retrospective study was conducted to investigate the effectiveness of immunotherapy combined with chemotherapy plus bevacizumab in treating EGFR/ALK-positive NSCLC patients who had progressed after previous TKI therapy, specifically those with brain metastases. The study analyzed data from 19 patients, including those with EGFR mutations, ALK translocations, and RET rearrangements. The overall response rate (ORR) and disease control rate (DCR) were 15.8% and 57.9% respectively, with intracranial ORR and extracranial ORR at 10.5% and 15.8% respectively. The intracranial and extracranial disease control rates were 68.4% and 63.2% respectively. The median progression-free survival (PFS) was 4.7 months, and the median overall survival (OS) was 19.2 months. The most common grade 3-4 adverse event was leukopenia, followed by neutropenia, thrombocytopenia, and rash. No severe adverse events leading to treatment discontinuation or death were observed. The study demonstrates that the combination of immunotherapy and chemotherapy plus bevacizumab may be effective and safe in treating NSCLC patients who have progressed after previous TKI therapy, with evidence of synergistic anti-tumor activity against brain metastases.

Asset Subtitle

Yutao Liu

Meta Tag

Speaker Yutao Liu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

retrospective study

immunotherapy

chemotherapy

bevacizumab

EGFR/ALK-positive NSCLC

TKI therapy

brain metastases

EGFR mutations

ALK translocations

RET rearrangements